SCHEMBL4414290

SCHEMBL4414290

Nc1ccn([C@@H]2O[C@H](C(O)Cl)[C@@H](O)[C@H]2O)c(=O)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.67
LMNA P02545 2/20 0.63
MTOR P42345 2/20 0.63
THRB P10828 1/20 0.63
MDM2 Q00987 1/20 0.63
NCOA1 Q15788 1/20 0.63
NCOA3 Q9Y6Q9 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.45
ST6GAL1 P15907 2/20 0.45
TSHR P16473 1/20 0.45
GLA P06280 1/20 0.45
P2RY2 P41231 1/20 0.45
PDE4D Q08499 1/20 0.44
PDE3A Q14432 1/20 0.44
SLC29A1 Q99808 1/20 0.44
GMNN O75496 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
NFKB1 P19838 1/20 0.44
DNMT1 P26358 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL800434 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL800348 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL4946500 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL223209 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL7539957 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL6312068 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL13134657 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL800395 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL13190277 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2
SCHEMBL800216 0.88 NT5E (0.65) NT5ELMNAMTORTHRBMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020177695-A1 Nucleic acid probes and methods DUKE UNIVERSITY 2002-11-28 US claimed
US-6288221-B1 REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES DUKE UNIVERSITY 2001-09-11 US claimed
CN-114246906-A Application of traditional Chinese medicine composition in preparation of medicines for preventing and treating bone marrow suppression 山东新时代药业有限公司 2022-03-29 CN disclosed
EP-3609534-A1 BROAD SPECTRUM INFLUENZA VIRUS VACCINE ModernaTX, Inc. (US) 2020-02-19 EP disclosed
WO-2018170245-A1 BROAD SPECTRUM INFLUENZA VIRUS VACCINE MODERNATX, INC. (US) 2018-09-20 WO disclosed
EP-3102215-A2 4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION Riboscience LLC (US) 2016-12-14 EP disclosed
WO-2015120237-A2 4'-DIFLUOROMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF INFLUENZA RNA REPLICATION RIBOSCIENCE LLC (US) 2015-08-13 WO disclosed
US-8252768-B2 Designer therapy of pancreatic tumors UNIVERSITY OF MIAMI (US) 2012-08-28 US disclosed
US-20090325897-A1 DESIGNER THERAPY OF PANCREATIC TUMORS UNIVERSITY OF MIAMI (US) 2009-12-31 US disclosed
EP-1520015-A2 PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE Knecht, Wolfgang (SE) 2005-04-06 EP disclosed
WO-2004003185-A2 PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE KNECHT WOLFGANG (SE) 2004-01-08 WO disclosed
US-20020177695-A1 Nucleic acid probes and methods DUKE UNIVERSITY 2002-11-28 US disclosed
US-6288221-B1 REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES DUKE UNIVERSITY 2001-09-11 US disclosed
EP-0233493-A2 Process for producing ribonucleosides Yamasa Shoyu Kabushiki Kaisha (JP) 1987-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177695-A1 Nucleic acid probes and methods NUDT1, NT5C3B, NT5C2 NT5E 9/4885LMNA 1665/4885MTOR 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.